GLP3-RT
A triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. Research investigates its effects on glucose regulation, adipose tissue metabolism, and energy expenditure. Studied in the context of metabolic syndrome and obesity models.
Unit Price
Sign in to view pricing.
Purchase requires a verified researcher account and a signed RUO attestation.
All batch test results and certificates of analysis are published below — including any batches that failed testing. Full transparency is our standard.
Mechanism of Action
Retatrutide (LY3437943) is a triple agonist targeting GLP-1, GIP, and glucagon receptors. GLP-1 activation enhances glucose-dependent insulin secretion and satiety; GIP agonism amplifies incretin response and modulates adipose tissue; glucagon receptor activation increases energy expenditure and hepatic lipid oxidation. Phase 2 trials showed up to 24.2% weight reduction at 48 weeks.
Research References
Full research page →Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315
Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised phase 2 trial. Lancet. 2023
Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022
Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024
Related Products
Batch History & Certificates of Analysis
Full Batch Record
Active Batches
RT10-2026-002
Received Apr 15, 2026
Qty Received
20 units
No test results on record for this batch.
RT10-2026-001
Received Apr 13, 2026
Qty Received
14 units
No test results on record for this batch.
For Research Use Only. This product is supplied exclusively for in vitro research, laboratory study, and experimental purposes. It is not a drug, supplement, food, or cosmetic, and is not intended for human or veterinary use. See our Compliance & RUO Policy.